COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Flumazenil Reversal of Oral Triazolam

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00695630
Recruitment Status : Completed
First Posted : June 12, 2008
Last Update Posted : June 12, 2008
National Institutes of Health (NIH)
Information provided by:
University of Washington

Brief Summary:
An increase in the utilization of anesthesia and sedation medications by non-anesthesiologists, including dentists, has grown dramatically. This has been prompted, in part, by the need for pharmacological tools to address high levels of fear and anxiety about dental care among the US population and the evidence of oral health disparities among those who are fearful . Given the prevalence of dental fear in the general population and in the various populations with the greatest burden of oral diseases, effective sedation techniques are needed that are safe and effective in the hands of general dentists that make up the "front line" in the efforts to reduce oral health disparities. This study is to determine whether, when compared to a saline placebo, a single intraoral submucosal administration of the benzodiazepine antagonist flumazenil (0.2 mg) is capable of attenuating in 10 minutes or less the central nervous system (CNS) depression produced by a paradigm of stacked sublingual dosing of triazolam (3 doses of 0.25 mg over 90 minutes).

Condition or disease Intervention/treatment Phase
Dental Anxiety Drug: Flumazenil Drug: Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Flumazenil Rescue Strategy
Study Start Date : September 2006
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anxiety
Drug Information available for: Flumazenil

Arm Intervention/treatment
Experimental: 1
Flumazenil 2mL
Drug: Flumazenil
2 mL, 0.2 mg SM

Placebo Comparator: 2
Saline, 2mL SM
Drug: Placebo
2 mL sterile saline SM

Primary Outcome Measures :
  1. Observer Assessment of Alertness/Sedation [ Time Frame: 360 minutes ]

Secondary Outcome Measures :
  1. BIS [ Time Frame: 360 minutes ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • ASA I

Exclusion Criteria:

  • Use of benzodiazepines, anxiolytics or any other medications that would interact with either triazolam's or flumazenil's metabolism or clinical effect (including herbals) within four weeks of the study
  • Body mass index (BMI) no less than 15 kg/m2 and no greater than 30 kg/m2
  • Pregnancy or not currently using pharmacologic methods of birth control
  • Allergy or sensitivity to benzodiazepines
  • History of a seizure disorder; AND
  • Chronic tobacco use.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00695630

Layout table for location information
United States, Washington
Dental Fears Research Clinic
Seattle, Washington, United States, 98195
Sponsors and Collaborators
University of Washington
National Institutes of Health (NIH)
Layout table for investigator information
Principal Investigator: Peter M Milgrom, DDS University of Washington
Layout table for additonal information
Responsible Party: Peter Milgrom/Professor of Dental Public Health Sciences, University of Washington Identifier: NCT00695630    
Other Study ID Numbers: 30779
U54DE014254 ( U.S. NIH Grant/Contract )
First Posted: June 12, 2008    Key Record Dates
Last Update Posted: June 12, 2008
Last Verified: June 2008
Keywords provided by University of Washington:
conscious sedation
dental anxiety/drug therapy
behavior/drug effects
Additional relevant MeSH terms:
Layout table for MeSH terms
Protective Agents
Physiological Effects of Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action